{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}],"title":"Stringent Complete Response"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"14"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"}],"title":"Very Good Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"9"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"title":"Minimal Response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}],"title":"Not evaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"description":"Response rate was assessed using the International Myeloma Working Group uniform response criteria. Stringent complete response, Complete Response, Very Good Partial Response, and Partial Response are defined in outcome measure 1.\n\n* MR included participants in whom some, but not all, criteria for PR were fulfilled, providing the remaining criteria satisfied the requirements for MR. Required all of the following:\n\n  * ≥25% to ≤ 49% reduction in the level of serum monoclonal protein for at least two determinations six weeks apart.\n  * If present, a 50 to 89% reduction in 24-hour light chain excretion, which still exceeds 200 mg/24 h, for at least two determinations six weeks apart.\n  * 25-49% reduction in the size of plasmacytomas (by clinical or radiographic examination) for at least six weeks.\n  * No increase in size or number of lytic bone lesions (development of compression fracture does not exclude response).\n* Stable Disease: Not meeting the criteria for minimal response or","groups":[{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG000","title":"High Risk Cytogenetics"},{"description":"Induction (Cycles 1-9): Lenalidomide orally, days 1-21. Bortezomib injection, days 1, 8, 15, 22. Dexamethasone orally, days 1, 2, 8, 9, 15, 16, 22, 23 (for subjects 75 years of age or younger), or Dexamethasone orally days 1, 8, 15, 22 (for subjects greater than 75 years of age)\n\nConsolidation (cycles 10-15): Lenalidomide po daily (1-21). Bortezomib sc on days 1, 15\n\nLenalidomide\n\nBortezomib\n\nDexamethasone","id":"OG001","title":"Low Risk Cytogenetics"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Response Rate With Respect to Cytogenetic Characteristics","type":"SECONDARY","unitOfMeasure":"Participants"}